日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors

BCL-2抑制剂维奈托克(VEN)和FLT3抑制剂吉瑞替尼(GIL)的多药联合疗法在急性髓系白血病细胞中的活性高于新型多药BCL-2/FLT3 VEN-GIL混合单分子抑制剂。

Goodis, Christopher C; Eberly, Christian; Chan, Alexandria M; Kim, MinJung; Lowe, Brandon D; Civin, Curt I; Fletcher, Steven

Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 Inhibitors

通过将 BCL-2 抑制剂维奈托克转化为多药理双重 BCL-2/HDAC1 抑制剂和双重 BCL-2/HDAC6 抑制剂来增强其抗白血病活性

Alexandria M Chan ,Christian Eberly ,Brandon Drennen ,Christopher C Goodis ,Zoe Wuyts ,Curt I Civin ,Steven Fletcher

Multimodal nanoparticle-containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation

含有多模式纳米颗粒的修饰型辛酰苯胺异羟肟酸聚合物缀合物可减轻严重炎症中的免疫功能障碍

Nhu Truong ,Andrea L Cottingham ,Shruti Dharmaraj ,Jacob R Shaw ,Jackline Joy Martin Lasola ,Christopher C Goodis ,Steven Fletcher ,Ryan M Pearson

Discovery of N-sulfonylated aminosalicylic acids as dual MCL-1/BCL-xL inhibitors

发现N-磺酰化氨基水杨酸作为MCL-1/BCL-xL双重抑制剂

Chen, Lijia; Chauhan, Jay; Yap, Jeremy L; Goodis, Christopher C; Wilder, Paul T; Fletcher, Steven

Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge

改性辛酰苯胺异羟肟酸可降低脂多糖炎症刺激下药物相关的免疫细胞死亡和器官损伤

Nhu Truong ,Christopher C Goodis ,Andrea L Cottingham ,Jacob R Shaw ,Steven Fletcher ,Ryan M Pearson

Recent applications of covalent chemistries in protein-protein interaction inhibitors

共价化学在蛋白质-蛋白质相互作用抑制剂中的最新应用

Chan, Alexandria M; Goodis, Christopher C; Pommier, Elie G; Fletcher, Steven